Â鶹´«Ã½

    Advertisement
    McKnight's Long-Term Care News07:49Ozempic Pharma
    Indian Express10:24Ozempic Pharma
    Clinical Trials Arena22:09Pharma
    pharmaphorum21:06Pharma
    KVLY-TV10:19Pharma
    Quartz05:17Pharma
    euronews22:06Eli Lilly Pharma
    Morningstar23:14Eli Lilly Pharma
    Kiplinger.com03:41Pharma
    Yahoo! US02:02Pharma
    Clinical Trials Arena22:38Pharma
    PMLiVE23:42Pharma
    Yahoo! UK & Ireland23:05Pharma
    Yahoo! US20:10Pharma
    Proactive Investors (US)03:45Pharma
    Investing.com UK02:29Pharma
    Sky News06:54Pharma
    In the last hour
    GlobeNewswire (Press Release)11:31
    Yesterday
    The Motley Fool22:16 1-Feb-25
    Law36013:55 1-Feb-25
    PR Newswire (Press Release)12:46 1-Feb-25
    BioWorld07:38 1-Feb-25
    Yahoo! UK & Ireland01:27 1-Feb-25
    In the last 7 days
    Yahoo! UK & Ireland23:05 31-Jan-25
    PR Newswire (Press Release)21:52 31-Jan-25
    Quartz21:03 31-Jan-25
    Yahoo! US20:10 31-Jan-25
    PR Newswire (Press Release)08:08 31-Jan-25
    McKnight's Long-Term Care News07:49 31-Jan-25
    GlobeNewswire (Press Release)04:48 31-Jan-25
    Investors Chronicle03:48 31-Jan-25
    Money Morning02:07 31-Jan-25
    PR Newswire (Press Release)21:45 30-Jan-25
    GlobeNewswire (Press Release)13:10 30-Jan-25
    Monocle11:20 30-Jan-25
    Indian Express10:24 30-Jan-25
    PharmTech.com08:46 30-Jan-25
    GlobeNewswire (Press Release)08:04 30-Jan-25
    BioPharma Dive03:45 30-Jan-25
    GlobeNewswire (Press Release)03:19 30-Jan-25
    ABC7 / WLS-TV02:30 30-Jan-25
    Business Wire (Press Release)01:35 30-Jan-25
    PMLiVE23:38 29-Jan-25
    pharmaphorum23:31 29-Jan-25
    Pharmaceutical Technology22:40 29-Jan-25
    Proactive Investors (US)19:18 29-Jan-25
    The Financial Express17:16 29-Jan-25
    GlobeNewswire (Press Release)14:12 29-Jan-25
    Law36013:35 29-Jan-25
    American Journal of Managed Care10:07 29-Jan-25
    Benzinga09:52 29-Jan-25
    TipRanks09:44 29-Jan-25
    Medpage Today08:48 29-Jan-25
    FiercePharma08:16 29-Jan-25
    Bloomberg Law08:15 29-Jan-25
    Forbes07:42 29-Jan-25
    ENDPOINTS07:29 29-Jan-25
    GlobeNewswire (Press Release)07:25 29-Jan-25
    Pharmacy Times07:21 29-Jan-25
    IPWatchdog.com06:57 29-Jan-25
    PR Newswire (Press Release)05:10 29-Jan-25
    The Fresno Bee05:04 29-Jan-25
    Pharmaceutical Technology04:33 29-Jan-25
    Zacks02:36 29-Jan-25
    Investing.com UK02:29 29-Jan-25
    PR Newswire (Press Release)21:51 28-Jan-25
    pharmaphorum21:06 28-Jan-25
    British Medical Journal20:35 28-Jan-25
    Business Wire (Press Release)15:11 28-Jan-25
    Business Wire (Press Release)14:19 28-Jan-25
    University of Bath13:52 28-Jan-25
    KVLY-TV10:19 28-Jan-25
    Law36009:53 28-Jan-25
    MPR News08:12 28-Jan-25
    Law36007:21 28-Jan-25
    Bloomberg Law07:01 28-Jan-25
    Sky News06:54 28-Jan-25
    Nasdaq06:18 28-Jan-25
    Quartz05:17 28-Jan-25
    KEYC News04:16 28-Jan-25
    FiercePharma03:59 28-Jan-25
    Bloomberg Law02:20 28-Jan-25
    TipRanks01:38 28-Jan-25
    Zacks01:08 28-Jan-25
    Morningstar23:14 27-Jan-25
    PR Newswire (Press Release)22:15 27-Jan-25
    Clinical Trials Arena22:09 27-Jan-25
    euronews22:06 27-Jan-25
    GlobeNewswire (Press Release)19:07 27-Jan-25
    Power Corridor12:48 27-Jan-25
    Yahoo! UK & Ireland18:11 26-Jan-25
    Business Wire (Press Release)02:08 26-Jan-25
    In the last month
    GlobeNewswire (Press Release)10:03 25-Jan-25
    GlobeNewswire (Press Release)09:33 25-Jan-25
    The Motley Fool09:31 25-Jan-25
    MorningStar.com08:39 25-Jan-25
    Fox News08:34 25-Jan-25
    GlobeNewswire (Press Release)07:55 25-Jan-25
    TipRanks07:32 25-Jan-25
    Proactive Investors (US)06:27 25-Jan-25
    Fortune04:25 25-Jan-25
    BioPharma Dive04:23 25-Jan-25
    Scrip Pharma Intelligence04:02 25-Jan-25
    Yahoo! UK & Ireland03:49 25-Jan-25
    The Motley Fool03:46 25-Jan-25
    Proactive Investors (US)03:45 25-Jan-25
    Kiplinger.com03:41 25-Jan-25
    Invezz03:29 25-Jan-25
    Wall Street Pit02:41 25-Jan-25
    Yahoo! UK & Ireland02:17 25-Jan-25
    Yahoo! US02:02 25-Jan-25
    Yahoo! US01:42 25-Jan-25
    Yahoo! US01:42 25-Jan-25
    FX Empire01:38 25-Jan-25
    ShareCast01:16 25-Jan-25
    Quartz01:06 25-Jan-25
    Yahoo! UK & Ireland00:46 25-Jan-25
    BNN Bloomberg00:08 25-Jan-25
    RTT News00:05 25-Jan-25
    pharmaphorum00:03 25-Jan-25
    TipRanks23:33 24-Jan-25
    FierceBiotech23:06 24-Jan-25
    ENDPOINTS23:04 24-Jan-25
    Benzinga22:55 24-Jan-25
    GlobeNewswire (Press Release)21:22 24-Jan-25
    New Zealand Herald10:13 24-Jan-25
    BioWorld02:40 24-Jan-25
    Pharmacy Times02:00 24-Jan-25
    Benzinga07:27 23-Jan-25
    FierceBiotech02:01 23-Jan-25
    Morningstar01:37 23-Jan-25
    Zacks00:02 23-Jan-25
    view more headlines
    2 Feb 11:31

    About our Novo Nordisk news

    Latest news on Novo Nordisk, a global healthcare company focused on diabetes care, obesity treatment, and other serious chronic diseases. Get updates on Novo Nordisk's products, research, financial performance, and stock price.

    Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company has grown to become a global leader in diabetes care, with a strong presence in the fields of hemophilia, growth hormone therapy, and obesity treatment. Novo Nordisk's key products include insulin analogs like Tresiba and Levemir, GLP-1 receptor agonists such as Victoza and Ozempic, and obesity drugs like Saxenda and Wegovy.

    Stay informed about the latest developments in Novo Nordisk's research and development pipeline, including updates on clinical trials, regulatory approvals, and new product launches. Our feed covers the company's ongoing efforts to innovate and improve treatments for diabetes, obesity, and other metabolic disorders, such as the development of oral semaglutide and the exploration of novel drug targets.

    In addition to product news, our Novo Nordisk feed keeps you updated on the company's financial performance, including quarterly earnings reports, sales figures, and market share data. We also cover key events and announcements that may impact Novo Nordisk's stock price (NYSE: NVO), such as strategic partnerships, acquisitions, and leadership changes.

    Beyond the business aspects, our feed highlights Novo Nordisk's commitment to corporate social responsibility and sustainability. From initiatives to improve access to diabetes care in developing countries to efforts to reduce the company's environmental footprint, we provide a comprehensive view of Novo Nordisk's impact on global health and society.

    As the prevalence of diabetes and obesity continues to rise worldwide, Novo Nordisk plays a crucial role in addressing these global health challenges. Our Â鶹´«Ã½ feed on Novo Nordisk brings you the most relevant and up-to-date information from reliable sources, helping you stay informed about this innovative and influential healthcare company.


    Publication filters

    Headline Density

    Sorry, no headlines or news topics were found. Please try different keywords.